Research
Neural
BI 1820237 treatment was associated with transient nausea and vomiting at higher doses.
Practitioners should monitor for gastrointestinal side effects when prescribing BI 1820237.
StrongSupportsmedium confidence
BI 1820237 treatment was associated with transient nausea and vomiting at higher doses.
Why this rating
Based on the randomized phase I study design.
Source
A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
Nadine Beetz et al. · Diabetes Obesity and Metabolism · 2024
rct · n=74Cited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →